Kratom: payment processing without the fragility

Why processors flag this vertical

• The FDA has not approved kratom as a drug, food additive, or dietary supplement and detains import shipments under Import Alert 54-15, which puts every vendor's supply chain under federal seizure risk.
• Kratom is banned at the state level in nine states, including Alabama, Arkansas, Indiana, Wisconsin, and, as of July 2026, Kansas and Tennessee, so a single national checkout can complete illegal sales unless geoblocking is enforced.
• The DEA's 2026 action to temporarily schedule concentrated 7-hydroxymitragynine (7-OH) products created acute uncertainty about which SKUs are lawful, and acquirers price uncertainty as risk.
• Ingestible botanicals with health-adjacent marketing draw FDA warning letters for disease claims, and a warning letter against a merchant is often an automatic termination trigger for its processor.
• Most PSPs, including Stripe, PayPal, and Square, prohibit kratom by policy, leaving the category dependent on a small set of high-risk acquirers whose appetite shifts with headlines.
• Local vape-and-smoke-shop retail channels and gray-market marketplaces have burned processors before, so new kratom applications inherit the category's loss history.

What drives chargebacks here

• Product-effect disputes from customers whose experience did not match potency expectations, a version of the not-as-described dispute that is endemic to ingestible botanicals.
• Item-not-received disputes when inventory gaps caused by FDA import detentions delay fulfillment.
• Unrecognized-charge disputes because vendors often use neutral descriptors to survive processor scrutiny, which backfires when customers do not connect the charge to the store.
• Subscription disputes on autoship programs where cancellation flows are buried, a pattern regulators and issuers both watch for in supplements-adjacent categories.

Processing challenges to expect

• Stripe, PayPal, Square, and Shopify Payments prohibit kratom, and Shopify has also restricted kratom sales at the platform level, so vendors frequently lose both processing and their storefront at once.
• High-risk acquirers that do board kratom typically impose rolling reserves, monthly volume caps, and ingredient and labeling review before approval.
• State bans and the 2026 7-OH scheduling action mean underwriting is SKU-level: an acquirer may approve plain leaf and powder but refuse extracts and 7-OH products entirely.
• Miscoding kratom as generic supplements or herbs to pass underwriting is common and is treated as transaction laundering when discovered, ending the relationship and poisoning future applications.
• Domestic acquirer appetite evaporates quickly on adverse regulatory news, and offshore acquiring, the fallback, brings higher pricing, FX cost, and settlement friction.

The infrastructure playbook

• Geofence checkout against banned states, currently including Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Tennessee, Vermont, and Wisconsin, and keep the blocklist maintained, because a processor audit that finds shipments into a ban state ends the account.
• Split your catalog by risk tier and route it accordingly: plain leaf and powder on your domestic high-risk MID, and treat extracts and any 7-OH product as unbankable domestically until the DEA scheduling picture settles.
• Carry at least two MIDs at different acquirers plus a vetted offshore backup relationship, since kratom loses domestic acquirers to headline risk faster than almost any other legal product.
• Vault customer cards in a processor-independent token vault so autoship subscribers survive an account termination, which in this vertical is a matter of when, not if.
• Scrub every product page and email for disease and treatment claims, and align labeling with KCPA-state requirements on age limits and alkaloid disclosure, because your marketing is part of the acquirer's audit surface.
• Use honest descriptors that match your brand, and lean on pre-chargeback alert networks to intercept disputes, rather than hiding behind a generic descriptor that inflates unrecognized-charge disputes.

Frequently asked questions

Is kratom legal to sell online in the US?

Federally, kratom is not a controlled substance and interstate sale is not itself illegal, but the FDA blocks imports under Import Alert 54-15 and nine states ban it, with Kansas and Tennessee bans taking effect July 1, 2026. Around eighteen states instead regulate it under Kratom Consumer Protection Acts with age limits and labeling rules. Selling online is viable, but only with state-level geoblocking and KCPA-compliant labeling built into your operation.

Why does every payment processor keep shutting my kratom store down?

Mainstream PSPs prohibit kratom outright, so accounts opened under generic descriptions get terminated when catalog scans or dispute patterns reveal the products. Even legitimate high-risk acquirers exit when regulatory news breaks, as happened around the DEA's 2026 move against 7-OH products. Stability comes from boarding transparently with kratom-approved acquirers, holding a backup MID, and keeping your subscriber card vault portable.

Can I still sell 7-OH or extract products?

Treat concentrated 7-OH products as radioactive. The DEA initiated temporary scheduling in 2026, several states already restrict or ban enhanced products even where leaf kratom is legal, and acquirers that tolerate plain leaf will terminate over extract SKUs. If you keep extracts in the catalog, isolate them from your primary MID and get written confirmation from your acquirer that the SKUs are approved.

Related verticals

• CBD & Hemp Products
• Nutraceuticals & Supplements
• Vape & E-Cigarettes
• All high-risk industries